Mivacurium dichloride (Mivacurium chloride) is a non-depolarising, rapid neuromuscular blocker of short duration, used therefore as anesthetic, to provide skeletal muscle relaxation in minor surgical operations, in emergency surgical procedures of short to intermediate duration and during intubation of the trachea.

Mivacurium caused pseudo-allergic reactions in wild-type mice by inducing mast cells to release histamine.?However, it did not induce a similar phenomenon in KitW-sh/W-sh mice.?Furthermore, MrgprB2-knockout mice displayed no inflammatory response to mivacurium.?Mivacurium induced LAD2 cell degranulation in a dose-dependent manner.?Mivacurium stimulated intracellular calcium ion (Ca2+) influx in MRGPRX2-HEK293 cells but not in NC-HEK293 cells.?However, mivacurium induced the release of only low levels of mediators in LAD2 cells transfected with MRGPRX2-targeted small interfering (si)RNA.?Notably, cytokine release was not observed in LAD2 cells even when stimulated with high concentrations of mivacurium[1].

Mivacurium is rapidly hydrolyzed in the plasma with a short duration of action(< 10 min). Mivacurium has lots of advantages, like a rapid effect, nonneurological toxicity and a lack of heart rate alteration. Mivacurium causes pseudo-allergic reactions in C57 wild-type mice by inducing mast cells to release histamine and a decrease in body temperature[1].